TeaTalkMagazine

News for Women – Dedicated to Living Your Best Life, with the Best Cuppa!

Bald person in vest looking up at buildings
Mens Health Teatalk Magazine News

Hope for balding Brits as new drug shows results ‘not seen in 30 years’

Millions of men with hair loss could be a step closer to a genuinely new treatment, after an experimental drug delivered results its makers are calling the biggest breakthrough in the field for more than three decades.

The drug, a topical solution called clascoterone, is designed specifically for male-pattern hair loss, the most common cause of baldness, which is estimated to affect around 6.5 million men in the UK and roughly 85% of men by the age of 50. In late-stage trials it produced significant hair regrowth, and unlike existing options it appears to do so without the bodily side effects that put many men off.

What the trials found

The results come from two large Phase 3 studies, SCALP 1 and SCALP 2, involving 1,465 adults across the US and Europe. One study showed a 539% relative improvement in “target area hair count” compared with a dummy treatment, while the second showed a 168% relative improvement. That headline figure is a comparison against placebo rather than a measure of hair multiplying fivefold, but researchers say the improvement was both measurable and noticeable to the men themselves.

Its manufacturer, Cosmo Pharmaceuticals, described the topline results as the “first major therapeutic breakthrough in hair-loss treatment in more than three decades.”

Why this drug is different

What sets clascoterone apart is how it works. It blocks dihydrotestosterone, the hormone behind male-pattern baldness, directly at the hair-follicle receptor, without being absorbed into the body more widely.

Professor Maria Hordinsky of the University of Minnesota, who was involved in the research, said: “Unlike existing treatments for androgenic alopecia, clascoterone 5% topical solution targets the androgen receptor locally in the hair follicle, without measurable systemic absorption. This addresses the biological root cause of hair follicle miniaturisation while avoiding the systemic side effects associated with oral therapies, such as reduced libido or sexual dysfunction.”

She added that the findings were encouraging on safety as well as growth: “The treatment showed an excellent safety profile. Treatment emergent adverse events were similar to vehicle, most were mild and unrelated to the study drug, and no sexual side effects were reported.”

That distinction matters, because the side effects of existing oral treatments, particularly the small risk of sexual dysfunction linked to finasteride, are a common reason men avoid or give up on them.

When could Brits get it?

This is the part to keep expectations in check on. Clascoterone is not yet approved, and won’t be available imminently. Cosmo has said it plans to submit the drug for regulatory approval in the US and Europe, but only once 12-month safety data is complete, with that data expected during the first half of 2026. Any approval would follow after that, meaning it is likely to be some time before a UK rollout. The same active ingredient, in a weaker 1% form, is already approved as an acne treatment, which may help its case as it moves through the process.

A spokesperson from uk hair experts at UK Hair Transplants said: “It’s genuinely encouraging to see a new approach for male-pattern hair loss, because the field has barely moved in 30 years, and the early data here is some of the most promising we’ve seen. But people deserve realism alongside the hope. This is still a trial-stage treatment that isn’t approved or available yet, and like the existing drugs it would need to be used continuously to keep any benefit, it’s not a permanent fix. Hair loss affects men very differently, and what works depends entirely on the cause and the stage.”